Abstract：
:We retrospectively evaluated the prognostic significance of polypharmacy and inappropriate medication use among 150 patients >60 years of age receiving induction chemotherapy for acute myelogenous leukemia (AML). After adjustment for age and comorbidity, increased number of medications at diagnosis (≥ 4 versus ≤ 1) was associated with increased 30-day mortality (OR=9.98, 95% CI=1.18-84.13), lower odds of complete remission status (OR=0.20, 95% CI=0.06-0.65), and higher overall mortality (HR=2.13, 95% CI=1.15-3.92). Inappropriate medication use (classified according to Beers criteria) was not significantly associated with clinical outcomes. Polypharmacy warrants further study as a modifiable marker of vulnerability among older adults with AML.
journal_name
Leuk Resjournal_title
Leukemia researchauthors
Elliot K,Tooze JA,Geller R,Powell BL,Pardee TS,Ritchie E,Kennedy L,Callahan KE,Klepin HDdoi
10.1016/j.leukres.2014.06.018subject
Has Abstractpub_date
2014-10-01 00:00:00pages
1184-90issue
10eissn
0145-2126issn
1873-5835pii
S0145-2126(14)00197-0journal_volume
38pub_type
杂志文章abstract：:Thirty-nine patients with Philadelphia chromosome-positive (Ph1) chronic myelocytic leukemia (CML) were monitored using cytofluorometry and cytogenetics. During chronic phase, abnormal populations could be detected using commercially available monoclonal antibodies. Most of these abnormal populations had either an HLA...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(85)90097-9
更新日期：1985-01-01 00:00:00
abstract：:The tumor promoting agent TPA (phorbol ester; 1.6 X 10(-8)M) was used to induce the differentiation in vitro of B-chronic lymphocytic leukemia (B-CLL) cells from 14 untreated patients. The uninduced phenotype was SIg+, Mrbc+, RFT-1+, RFA-4-, FMC7-. After 72 h incubation with TPA, B-CLL cells became RFA-4+, FMC7+ and l...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(84)90005-5
更新日期：1984-01-01 00:00:00
abstract：:The amplified myeloma centrosome has been identified as a therapeutic target. The present study explored the expression and prognostic significance of the centrosome-associated protein PLK1 in myeloma and the effect of BI 2536, a potent and selective inhibitor of PLK1, on myeloma cells. High plasma cell expression of ...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2011.07.016
更新日期：2011-12-01 00:00:00
abstract：:Proto-oncogene transcriptional activation was analyzed in a group of MCF 247 MuLv-induced T-cell lymphomas to identify transformation-specific gene activations and determine whether the proviral insertion near a myc gene could promote a peculiar mechanism of transformation through a differential proto-oncogene express...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(90)90007-v
更新日期：1990-01-01 00:00:00
abstract：:Effects of the HDAC inhibitor LBH-589 (panobinostat) on fludarabine lethality toward acute myeloid leukemia (AML) cells were examined in vitro and in vivo. LBH-589 pretreatment sensitized U937, HL-60, and primary leukemia cells to fludarabine while blocking NF-κB activation accompanied by XIAP down-regulation and JNK ...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2011.10.020
更新日期：2012-04-01 00:00:00
abstract：:Hemopoietic responses were studied in splenectomized mice after transplantation of the hemopoietic colony stimulating activity producing leukemia, L8313. In non-splenectomized mice, the number of peripheral leukocytes was elevated to 4 x 10(5)/mm3 after transplantation. In contrast, it was below 1.7 x 10(4)/mm3 in spl...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(89)90159-8
更新日期：1989-01-01 00:00:00
abstract：:This study uses single cell network profiling (SCNP) to characterize biological pathways associated with in vitro resistance or sensitivity to chemotherapeutics commonly used in acute myeloid leukemia (AML) (i.e. cytarabine/daunorubicin, gemtuzumab ozogamicin (GO), decitabine, azacitidine, clofarabine). Simultaneous m...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2012.02.022
更新日期：2012-07-01 00:00:00
abstract：BACKGROUND:T- cell prolymphocytic leukemia (T- PLL) is a rare aggressive hematological malignancy. Alemtuzumab, an anti-CD52 humanized monoclonal antibody, is the treatment of choice for remission induction. Allogeneic hematopoietic cell transplantation (allo-HCT) has been described to induce durable remissions and imp...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2018.01.009
更新日期：2018-04-01 00:00:00
abstract：:Stem cell factor (SCF) is a growth factor that promotes the survival, proliferation, and differentiation of hematopoietic cells. SCF and its receptor, Kit, are normally present in both cell surface and soluble forms. Both forms of Kit can bind SCF. However, the function of soluble Kit is unknown. In order to determine...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/s0145-2126(00)00122-3
更新日期：2001-05-01 00:00:00
abstract：:A national cooperative group trial was conducted in 153 patients with chronic myelogenous leukemia (CML) in chronic phase treated with oral pulse busulfan to determine if oral vitamin A can increase the time to blast crisis and enhance survival of patients. Patients diagnosed within 1 year and in the chronic phase of ...
journal_title：Leukemia research
pub_type： 临床试验,杂志文章,多中心研究,随机对照试验
doi：10.1016/0145-2126(95)00032-j
更新日期：1995-09-01 00:00:00
abstract：:Hyaluronan (HA) modulates multidrug resistance (MDR) as well as cell migration. Tiam1 is involved in cytoskeleton reorganization during tumor invasion. In this report we show the relationship among HA, Tiam1, migration and MDR in murine lymphoma cell lines. We observed that MDR cells presented higher migratory capacit...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2010.02.020
更新日期：2010-11-01 00:00:00
abstract：:Blastic transformation of myeloproliferative neoplasms (MPN) is still poorly understood. We describe a cohort of 23 Roswell Park Cancer Institute (RPCI) patients and 89 additional cases from the English literature for whom biologic features were described. We initially compared our 23 patients to the 89 cases from the...
journal_title：Leukemia research
pub_type： 杂志文章,评审
doi：10.1016/j.leukres.2010.07.031
更新日期：2011-05-01 00:00:00
abstract：OBJECTIVES:Follicular lymphoma (FL) is generally considered an indolent disorder but a significant subset of patients shows a worse outcome. Aim of this study was to validate the FLIPI score in an independent series of follicular lymphoma patients and to correlate prognostic categories with the period of diagnosis and ...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2005.07.006
更新日期：2006-03-01 00:00:00
abstract：:Dequalinium (DQA) has been proposed as a selective antitumoral agent due to its preferential accumulation in mitochondria of cancer cells. Our aim was a better understanding of DQA cytotoxicity. DQA-induced NB4 and K562 cell alterations are initiated within the first 30 min of treatment at a high DQA concentration wit...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2006.11.018
更新日期：2007-07-01 00:00:00
abstract：:The treatment of acute myeloid leukemia (AML) did not evolve profoundly in the last decades. Some improvement has been made for acute lymphoblastic leukemia (ALL). Emerging new treatment modalities, such as immunotherapy, are now beginning to be available for acute leukemia, mostly for patients suffering from ALL. Thi...
journal_title：Leukemia research
pub_type： 杂志文章,评审
doi：10.1016/j.leukres.2017.06.011
更新日期：2017-09-01 00:00:00
abstract：:Ras proteins are frequently over-expressed in leukemia and contribute to leukemogenesis. We evaluated the anti-leukemic efficacy of a new third-generation bisphosphonate, ONO5920/YM529 (YM529). YM529 prevents the prenylation of Ras proteins and inhibited the growth of leukemic cells including a P-glycoprotein (P-gp) o...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2004.10.004
更新日期：2005-04-01 00:00:00
abstract：:Acute monocytic leukemia (M5) is a subtype of acute myeloid leukemia (AML) with two distinct morphologic subcategories, M5a and M5b. We compared the immunophenotype, cytogenetics and clinical outcome of AML M5 with non-M5 AML and also compared M5a with M5b. One hundred and twelve M5 (76 M5a, 36 M5b) and 726 non-M5 cas...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2007.06.019
更新日期：2008-02-01 00:00:00
abstract：:We designed a pharmacokinetic and pharmacodynamic phase I study of sequential topotecan (2.55-6.3mg/m2) by 72h infusion followed by five daily doses of etoposide for patients with refractory acute leukemia based upon synergistic anti-tumor activity of topoisomerase I and II inhibitors in vitro. Eight of the 29 patient...
journal_title：Leukemia research
pub_type： 临床试验,杂志文章
doi：10.1016/s0145-2126(02)00079-6
更新日期：2003-01-01 00:00:00
abstract：:To further understand the role of XIAP in acute myeloid leukemia (AML), we suppressed XIAP expression by antisense oligonucleotides and determined the effect on gene expression profiles and biological pathways. XIAP inhibition upregulated expression of proteasome genes in a manner similar to the proteasome inhibitor b...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2013.04.018
更新日期：2013-08-01 00:00:00
abstract：:This retrospective study of the thrombocythemia Italian registry (RIT) documented that 71 (30.6%) out of 232 ET patients experienced 88 cardiovascular adverse events (CV-AEs) during anagrelide treatment (522 pt-y). The rate of CV-AEs was: 24.1% for palpitations, 4.3% for angina, 3.5% for arterial hypertension, 3.0% fo...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2011.06.030
更新日期：2011-12-01 00:00:00
abstract：:Twenty-three patients with acute myelogenous leukemia (AML) in first relapse were treated with high-dose cytosine-arabinoside (Ara-C) and amsacrine or idarubicin. To prime the cells, the patients were given rhGM-CSF. We studied the influence of 48-h infusion of rhGM-CSF on proliferation and Ara-C sensitivity of leukem...
journal_title：Leukemia research
pub_type： 临床试验,杂志文章
doi：10.1016/0145-2126(96)00005-7
更新日期：1996-06-01 00:00:00
abstract：:Mutations in Janus kinase 2 (JAK2) are implicated in the pathogenesis of Philadelphia-chromosome negative myeloproliferative neoplasms, including primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Gandotinib (LY2784544), a potent inhibitor of JAK2 activity, shows increased potency for the JAK2V61...
journal_title：Leukemia research
pub_type： 杂志文章,多中心研究
doi：10.1016/j.leukres.2017.08.010
更新日期：2017-10-01 00:00:00
abstract：:Analgesic use has been implicated in the chemoprevention of a number of solid tumors, but to date no previous research has focused on the role of analgesics in the etiology of multiple myeloma (MM). We conducted a hospital-based case-control study of 117 patients with primary, incident MM and 483 age and residence mat...
journal_title：Leukemia research
pub_type： 杂志文章,随机对照试验
doi：10.1016/j.leukres.2006.07.027
更新日期：2007-04-01 00:00:00
abstract：:Many elderly patients with newly diagnosed acute myeloid leukemia (AML) present with cardiac comorbidity precluding the use of anthracycline containing chemotherapy regimens. Amsacrine, a topoisomerase II inhibitor, has been proposed as possible alternative to anthracyclines. Here, we report about the combination of a...
journal_title：Leukemia research
pub_type： 临床试验,杂志文章
doi：10.1016/j.leukres.2007.06.015
更新日期：2008-03-01 00:00:00
abstract：:Quantitative differences in HLe-1 expression were studied on normal lymphocytes and lymphoblasts of patients with acute lymphoblastic leukemia (ALL). A relationship was found between quantitative antigen expression and therapeutic outcome. Alterations in fluorescence intensity (FI) were demonstrated using quantitative...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(87)90110-x
更新日期：1987-01-01 00:00:00
abstract：:The effect of mesna on intracellular accumulation of cytosine arabinoside (Ara-C) in murine normal and neoplastic lymphocytes was studied. Simultaneous exposure of cells to mesna at concentrations ranging from 0.25 to 1.0 mM and 3H-Ara-C (40.0 nM) resulted in a strong inhibition of Ara-C uptake in normal lymphocytes. ...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(93)90117-4
更新日期：1993-09-01 00:00:00
abstract：:Imatinib is a tyrosine kinase inhibitor and is now used regularly in chronic myeloid leukaemia therapy in chronic phase with great success. This drug due its very nature of action is suspected to be teratogenic hence the patients are counseled not to get pregnant while on this drug. However in world literature few nor...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2008.03.007
更新日期：2008-10-01 00:00:00
abstract：:Screening for loss of heterozygosity (LOH) of the panel of 18 highly polymorphic microsatellite markers, especially from the region 11p15, was carried out on 154 samples from 26 patients with acute myeloid leukemia and eight with myelodysplastic syndromes (MDS). LOH was detected at the majority (72%) of the loci teste...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/s0145-2126(00)00086-2
更新日期：2001-01-01 00:00:00
abstract：:Hematopoiesis is regulated by several cytokines with pleiotropic activity. Several evidences have clearly demonstrated that these molecules, formerly regarded as specific for the hematopoietic system, also affect certain endothelial cell functions and that hematopoietic factors clearly influence angiogenesis. This rev...
journal_title：Leukemia research
pub_type： 杂志文章,评审
doi：10.1016/j.leukres.2012.02.003
更新日期：2012-05-01 00:00:00
abstract：:ABCG2 encodes a transporter protein that is associated with multidrug-resistant phenotypes in many cancers, including acute myeloid leukemia (AML); high levels of expression are generally associated with a poor prognosis. To better understand how expression of ABCG2 is controlled in pediatric AML, we performed a detai...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2011.05.004
更新日期：2011-10-01 00:00:00
